Insulet Corp.
Income Statement
| Line Item | FY2010 | FY2009 | FY2008 | FY2007 | FY2006 |
|---|---|---|---|---|---|
| Revenue | $98.1M | $65.0M | $36.2M | $15.5M | $3.5M |
| U.S. Omnipod | $92.7M | $62.6M | $34.5M | $14.8M | $3.5M |
| International Omnipod | $0 | $0 | $0 | $0 | $0 |
| Drug Delivery | $5.4M | $2.4M | $1.7M | $700.0K | $0 |
| Neighborhood Diabetes | $0 | $0 | $0 | $0 | $0 |
| Cost of Revenue | $53.2M | $47.7M | — | — | — |
| Gross Profit | $43.7M | $18.3M | — | — | — |
| Gross Margin | 44.6% | 28.1% | — | — | — |
| Operating Expenses | |||||
| Research & Development | $16.6M | $13.2M | — | — | — |
| SG&A Expense | $26.7M | $26.8M | — | — | — |
| Operating Income | $-38.6M | $-59.4M | — | — | — |
| Operating Margin | -39.4% | -91.3% | — | — | — |
| Interest Expense | — | — | — | — | — |
| Pretax Income | $-61.2M | $-72.3M | — | — | — |
| Income Tax Expense | — | — | — | — | — |
| Net Income | $-61.2M | $-72.3M | — | — | — |
| Net Margin | -62.3% | -111.3% | — | — | — |
| EPS (Basic) | $-1.54 | $-2.43 | — | — | — |
| EPS (Diluted) | $-1.54 | $-2.43 | — | — | — |
| Shares Outstanding (Basic) | — | — | — | — | — |
| Shares Outstanding (Diluted) | — | — | — | — | — |
| Dividends Per Share | — | — | — | — | — |